United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer announced that it's advancing its oral weight-loss treatment, called danuglipron, to the next round in an ongoing study after seeing "encouraging" results.

Pfizer advances once-daily weight-loss pill in ongoing study

Eli Lilly

We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly.

Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick?

Pfizer stock jumped early Thursday after the drugmaker said it selected a once-daily pill to move forward as a potential weight-loss drug.

Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug

Pfizer Inc (NYSE: PFE) is in focus today after announcing plans of proceeding with a once-a-day formulation of danuglipron – its weight-loss drug.  Encouraging data from an ongoing early-stage study informed its decision to move forward with that variant of its obesity pill.

Pfizer joins the weight-loss drug race again

British American Tobacco

CVS Health

Oaktree Specialty Lending

Procter & Gamble

Starbucks

Verizon

Seven companies offer a safety net against market volatility and constant dividend payments for those looking for a stable source of income. High-yield dividend companies are particularly appealing in the uncertain, higher-for-longer economic environment.

7 High-Yield Dividend Stocks to Buy and Hold Forever: July Edition

Pfizer is advancing the development of its once-daily weight loss pill, danuglipron.

Pfizer Moves Forward With Weight-Loss Pill. The Stock Is Rising.

Pfizer Inc.'s stock PFE rose 2.4% early Thursday, after the drug company said it has identified and selected a formulation for its once-daily pill to treat obesity. “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates,” Dr. Mikael Dolsten, chief scientific officer and president of R&D said in a statement. “The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space.” The company is...

Pfizer says it has identified and selected a preferred formulation for its one-a-day obesity pill

Pfizer said it will continue to develop the once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an early-stage trial. The company plans to conduct studies in the second half of the year evaluating multiple doses of the drug.

Pfizer moves forward with once-daily version of weight loss pill after setbacks

Pfizer said on Thursday it would advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year, sending its shares 5% higher in premarket trading.

Pfizer moves forward with once-daily weight loss pill

Hercules Capital

Target

One reason to invest in stocks is to generate a stable income that can help finance your life without having to work all the time. This includes investing in high-dividend stocks.

3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies. “Obesity.

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

Abbott Labs

AstraZeneca

Intuitive Surgical

Merck

PACS Group, Inc.

Tenet Healthcare

In my view, it's important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation.

7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns

NIKE

Tencent Holdings Limited

There's a popular perception that investors have to look at smaller companies to find the biggest gains. And, sure, there is a grain of truth to the underlying sentiment.

The 3 Most Undervalued Large-Cap Stocks to Buy in July 2024

Pfizer's cash flow from operations in 2022 was $29.267 billion, driven by COVID-19 vaccine and Paxlovid sales, but dropped to $8.7 billion in 2023. Despite revenue loss from COVID-19 drugs, the Company has a strong drug pipeline and scale advantage over rivals. Facing patent expirations and challenges from the US Inflation Reduction Act, PFE focuses on oncology drugs, biologics, and future revenue growth.

Pfizer: Buy This Big Yielder On The Strong Pipeline

Pfizer said on Tuesday its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.

Pfizer's longtime science chief Mikael Dolsten to step down

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career. This process is expected to last several months, probably through early next year. Pfizer will initiate an external search for a new Chief Scientific Officer, and Dr. Dolsten will assist i.

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.

Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade

Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births

Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point. The company's current pipeline of new product developments looks promising, and two recent FDA approvals underscore its ability to deliver new products to the market. I expect more full-year EPS guidance upgrades soon, as it appears that the company is moving ahead of management's initial cost-cutting plans.

Pfizer: The Inflection Point Is Here

Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.

Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock

Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.

Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?

Walgreens

Uncovering bargain stocks poised for substantial growth is hard. Understanding which stocks to buy can significantly impact investment success as the world navigates through the complexities of market trends and economic landscapes.

3 Bargain Stocks With the Potential for Mind-Boggling Returns

Ares Capital

Bristol-Myers

Pfizer's been raising its dividend payout for 15 years, and a heap of new products could help it continue the streak. The largest publicly traded business development company, Ares Capital offers investors a yield above 9% at recent prices.

3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July

Alibaba

PayPal

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings growth projections, and some highly attractive dividend yields, they present a hopeful picture for income and value-oriented investors.

3 Stock Giants Analysts Are Bullish On Despite Struggles

AT&T

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

News for Pfizer Stock (PFE)